CALQUENCE (acalabrutinib) - Mantle cell lymphoma (MCL)
Opinions on drugs -
Posted on
Jan 30 2026
Reason for request
Inclusion on list
Summary of opinion
Unfavourable opinion for reimbursement in the indication: “in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT)”.
Clinical Benefit
| Insufficient |
The clinical benefit of CALQUENCE (acalabrutinib) is insufficient in the MA indication. |
Clinical Added Value
| Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments
